Table 4 Clinical characteristics of patients with cTnT peak value ≤ 0.34 mg/l vs. cTnT peak value > 0.34 mg/l
Variables | Group III (n = 424) | Group IV (n = 140) | P |
|---|---|---|---|
Male sex (n, %) | 341 (80.4) | 102 (72.9) | 0.059 |
Age (y) | 65.40 ± 8.20 | 64.99 ± 8.21 | 0.608 |
Weight (kg) | 70.33 ± 10.51 | 69.18 ± 10.02 | 0.255 |
Height (cm) | 166.92 ± 6.68 | 166.48 ± 7.03 | 0.502 |
BMI (kg/m2) | 25.21 ± 3.25 | 24.92 ± 2.96 | 0.351 |
BSA (m2) | 1.77 ± 0.16 | 1.75 ± 0.16 | 0.256 |
Types of CAD | 0.127 | ||
Unstable angina pectoris (n, %) | 250 (59.0) | 82 (58.6) | |
Acute myocardial infarction (n, %) | 50 (11.8) | 25 (17.9) | |
Stable angina pectoris (n, %) | 124 (29.2) | 33 (23.6) | |
Diabetes mellitus (n, %) | 155 (36.6) | 46 (32..9) | 0.428 |
Hypertension (n, %) | 302 (71.2) | 111 (79.3) | 0.062 |
Cerebrovascular disease | 0.525 | ||
Stroke (n, %) | 16 (3.8) | 6 (4.3) | |
Lacunar infarction (n, %) | 111 (26.2) | 30 (21.4) | |
Peripheral vascular disease (n, %) | 8 (1.9) | 5 (3.6) | 0.249 |
Preoperative atrial fibrillation (n, %) | 12 (2.8) | 3 (2.1) | 0.661 |
Pulmonary hypertension (n, %) | 7 (1.7) | 5 (3.6) | 0.172 |
Serum creatinine (μmol/l) | 80.83 ± 19.83 | 87.59 ± 34.83 | 0.005 |
Ccr (ml/min/1.73 m2) | 81.58 ± 24.74 | 76.39 ± 25.81 | 0.034 |
Renal failure (n, %) | 2 (0.5) | 2 (1.4) | 0.242 |
LVEF (%) | 0.867 | ||
LVEF ≥ 45% (n, %) | 413 (97.4) | 136 (97.1) | |
LVEF < 45% (n, %) | 11 (2.6) | 4 (2.9) | |
Triple vessel disease (n, %) | 379 (89.4) | 126 (90.0) | 0.837 |
COPD (n, %) | 7 (1.7) | 2 (1.4) | 0.856 |
Previous PCI (n, %) | 2 (0.5) | 0 (0) | 0.416 |
NYHA | 0.673 | ||
I (n, %) | 25 (5.9) | 5 (3.6) | |
II (n, %) | 308 (72.6) | 107 (76.4) | |
III (n, %) | 86 (20.3) | 27 (19.3) | |
IV (n, %) | 5 (1.2) | 1 (0.7) | |
EuroSCORE II | 1.75 ± 0.94 | 1.92 ± 1.02 | 0.075 |
Operating time (min) | 263.00 ± 59.08 | 282.96 ± 75.44 | 0.001 |
Number of bypass grafts (n) | 3.68 ± 1.11 | 3.76 ± 0.97 | 0.446 |
Number of arterial grafts (n) | 1.44 ± 0.87 | 1.35 ± 0.80 | 0.274 |
Number of venous grafts (n) | 2.22 ± 1.12 | 2.44 ± 1.09 | 0.044 |
Total artery bypass grafting (n, %) | 36 (8.5) | 6 (4.3) | 0.100 |
Total vein bypass grafting (n, %) | 22 (5.2) | 13 (9.3) | 0.081 |
Peak of CK-MB (mg/l) | 18.00 (13.50, 25.00) | 41.00 (28.30, 69.85) | < 0.001 |
Peak of cTnT (mg/l) | 0.11 (0.10, 0.18) | 0.73 (0.44, 1.12) | < 0.001 |
CK-MB peak occurrencewithin 24 h (n, %) | 272 (64.2) | 114 (78.6) | 0.002 |
CK-MB peak value > 32.00 mg/l (n, %) | 47 (11.1) | 92 (65.7) | < 0.001 |
Follow-up time (month) | 75.75 (60.63, 93.34) | 75.45 (46.05, 95.33) | 0.578 |
Mid-term mortality (n, %) | 37 (8.7) | 23 (16.4) | 0.010 |